HATFIELD, Pa., June 2, 2016 /PRNewswire/ — Genisphere LLC, provider of the 3DNA® drug delivery platform, today announced it has executed a collaborative research and option to license agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
Under the agreement, MedImmune and Genisphere will develop novel nanoparticles utilizing its 3DNA dendrimer scaffold with up to six MedImmune oncology molecules, as the nanoparticle configuration may help to improve targeting of the drug.
According to the agreement, Genisphere will receive an upfront payment, development milestones and future royalties upon MedImmune triggering an option, and development and commercialization of therapeutics stemming from the collaboration. No additional financial terms of the agreement were disclosed.
The agreement announced today is the creation of a formal partnership between the companies following a two-year R&D collaboration to customize 3DNA nanoparticles for various applications at MedImmune.
Tom Bliss, Genisphere's Chief Executive Officer, said, "We have been very impressed with the forward thinking and highly collaborative nature of our partners at MedImmune and their willingness to explore novel ways to deliver novel oncology therapeutics. I am confident the flexibility of the 3DNA platform will help ensure success."
Genisphere will attend partnering sessions at the BIO international convention in San Francisco from June 6-9 to expand collaborations using the 3DNA platform for targeted drug delivery.
About Genisphere
Genisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic-acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead compounds based on 3DNA® nanotechnology. For more information, please visit http://genisphere.com
For more information contact:
Tom Bliss
Genisphere
215-996-3027
Email